Search

Displaying results 4181 - 4190 of 10000 in total
  1. Drug

    Peptide YY (3-36)

    go.drugbank.com/drugs/DB05004
    Investigational

    Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity. It reduces appetite and increases satiety in obese patients.

  2. Drug

    R1204

    go.drugbank.com/drugs/DB05118
    Experimental

    R1204 is G-protein-coupled receptor modulator. It is developed for the treatment of depression.

  3. Drug

    MK-4721

    go.drugbank.com/drugs/DB05933
    Investigational

    MK-4721 is a fully human monoclonal antibody directed to Agensys’ proprietary target Prostate Stem Cell Antigen (PSCA), an antigen expressed at significant levels on tumor cells from the majority of patients

  4. Drug

    Vicriviroc

    go.drugbank.com/drugs/DB06652
    Investigational

    Vicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1.

  5. Drug

    NGD-4715

    go.drugbank.com/drugs/DB06027
    Experimental

    NGD-4715 is an investigational compound developed for the treatment of Obesity. NGD-4715 functions as a melanin-concentrating hormone receptor 1 antagonist.

  6. Drug

    ARG098

    go.drugbank.com/drugs/DB06338
    Experimental

    ARG098 (anti-Fas IgM monoclonal antibody) was studied in a Phase I clinical trial in 2007 involving patients with rheumatoid arthritis.

  7. Drug

    Carteolol

    go.drugbank.com/drugs/DB00521
    Approved

    A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.

  8. Drug

    Crotalus scutulatus antivenin

    go.drugbank.com/drugs/DB13891
    Approved

    Since it was approved by the Food and Drug Administration in October 2000, crotalidae poyvalent immune Fab (CroFab) has largely replaced previously used crotaline antivenom. … Specimens with type A venom, which cause a different pattern of injury than other rattlesnakes, have been reported in southern California, Nevada, Utah, Arizona, Texas, and New Mexico [L2856].

  9. Drug

    PPI-2458

    go.drugbank.com/drugs/DB05864
    Investigational

    In preclinical studies to date, PPI-2458 has demonstrated the potent pharmacologic activity of this class of compounds while displaying an improved pharmacokinetic and toxicity profile. … This class of compounds has been shown to prevent both abnormal cell growth and the formation of new blood vessels (known as angiogenesis), which contribute to the growth of aberrant tissues in diseases

  10. Drug

    Sulfisoxazole

    go.drugbank.com/drugs/DB00263
    ApprovedVet approved

    A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.

    Synonyms: N'-(3,4)Dimethylisoxazol-5-yl-sulphanilamide, 4-Amino-N-(3,4-dimethyl-5-isoxazolyl)benzenesulfonamide